These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34129685)

  • 1. Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients.
    Leino AD; Park JM; Pasternak AL
    Pharmacotherapy; 2021 Aug; 41(8):649-657. PubMed ID: 34129685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.
    Yanik MV; Seifert ME; Locke JE; Hauptfeld-Dolejsek V; Crowley MR; Cutter GR; Mannon RB; Feig DI; Limdi NA
    Pediatr Transplant; 2019 Aug; 23(5):e13494. PubMed ID: 31124575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP3A5 Genetic Polymorphism on Long-Term Renal Function in Chinese Kidney Transplant Recipients Using Limited Sampling Strategy and Abbreviated Area Under the Curve for Tacrolimus Monitoring.
    Cheung CY; Chan KM; Wong YT; Chak WL; Bekers O; van Hooff JP
    Prog Transplant; 2020 Sep; 30(3):249-253. PubMed ID: 32552577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients.
    Asempa TE; Rebellato LM; Hudson S; Briley K; Maldonado AQ
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29161757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of De Novo Donor-specific HLA Antibodies and AMR in Renal Transplant Patients Depends on CYP3A5 Genotype.
    Friebus-Kardash J; Nela E; Möhlendick B; Kribben A; Siffert W; Heinemann FM; Eisenberger U
    Transplantation; 2022 May; 106(5):1031-1042. PubMed ID: 34241984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
    Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
    Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.
    Tang HL; Xie HG; Yao Y; Hu YF
    Pharmacogenet Genomics; 2011 Nov; 21(11):713-20. PubMed ID: 21886016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.
    Ghafari S; Dashti-Khavidaki S; Khatami MR; Ghahremani MH; Seyednejad SA; Beh-Pajooh A
    Iran J Kidney Dis; 2019 Nov; 13(6):414-416. PubMed ID: 31880588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.
    Hesselink DA; van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Zeier M; Budde K; Kuypers DR; Pisarski P; Le Meur Y; Mamelok RD; van Gelder T
    Pharmacogenet Genomics; 2008 Apr; 18(4):339-48. PubMed ID: 18334918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation.
    Ro H; Min SI; Yang J; Moon KC; Kim YS; Kim SJ; Ahn C; Ha J
    Ther Drug Monit; 2012 Dec; 34(6):680-5. PubMed ID: 23149441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.
    Gijsen V; Mital S; van Schaik RH; Soldin OP; Soldin SJ; van der Heiden IP; Nulman I; Koren G; de Wildt SN
    J Heart Lung Transplant; 2011 Dec; 30(12):1352-9. PubMed ID: 21930396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
    Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
    J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a pilot study.
    Gijsen VM; van Schaik RH; Soldin OP; Soldin SJ; Nulman I; Koren G; de Wildt SN
    Ther Drug Monit; 2014 Apr; 36(2):152-8. PubMed ID: 24089076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data.
    Deininger KM; Anderson HD; Patrinos GP; Mitropoulou C; Aquilante CL
    Pharmacogenomics J; 2024 May; 24(3):14. PubMed ID: 38750044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CYP3A5 Genetic Polymorphism on Intrapatient Variability of Tacrolimus Exposure in Chinese Kidney Transplant Recipients.
    Cheung CY; Chan KM; Wong YT; Chak WL; Bekers O; van Hooff JP
    Transplant Proc; 2019; 51(6):1754-1757. PubMed ID: 31255354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers.
    Reininger KA; Onyeaghala G; Anderson-Haag T; Schladt DS; Wu B; Guan W; Dorr CR; Remmel RP; Mannon R; Matas AJ; Oetting WS; Stahler P; Israni AK; Jacobson PA
    Clin Transplant; 2023 Apr; 37(4):e14893. PubMed ID: 36571802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients.
    Largeau B; Guellec CB; Longuet H; Lesne P; Bouvarel A; Préteseille L; Marquet P; Halimi JM; Büchler M; Gatault P; Noble J
    Prog Transplant; 2019 Dec; 29(4):300-308. PubMed ID: 31514576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
    Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX
    Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP3A5 Genotype and Time to Reach Tacrolimus Therapeutic Levels in Renal Transplant Children.
    Alvarez-Elías AC; García-Roca P; Velásquez-Jones L; Valverde S; Varela-Fascinetto G; Medeiros M
    Transplant Proc; 2016 Mar; 48(2):631-4. PubMed ID: 27110018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.